These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12093102)

  • 1. Effect of chronic treatment with riluzole on the nigrostriatal dopaminergic system in weaver mutant mice.
    Douhou A; Debeir T; Murer MG; Do L; Dufour N; Blanchard V; Moussaoui S; Bohme GA; Agid Y; Raisman-Vozari R
    Exp Neurol; 2002 Jul; 176(1):247-53. PubMed ID: 12093102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.
    Carbone M; Duty S; Rattray M
    BMC Neurosci; 2012 Apr; 13():38. PubMed ID: 22480308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
    Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sparing of the dopaminergic neurons containing calbindin-D28k and of the dopaminergic mesocortical projections in weaver mutant mice.
    Gaspar P; Ben Jelloun N; Febvret A
    Neuroscience; 1994 Jul; 61(2):293-305. PubMed ID: 7969910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production.
    Sajadi A; Bauer M; Thöny B; Aebischer P
    J Neurochem; 2005 Jun; 93(6):1482-6. PubMed ID: 15935064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
    Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ
    Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
    Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
    Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The intrastriatal injection of thrombin in rat induced a retrograde apoptotic degeneration of nigral dopaminergic neurons through synaptic elimination.
    Herrera AJ; de Pablos RM; Carreño-Müller E; Villarán RF; Venero JL; Tomás-Camardiel M; Cano J; Machado A
    J Neurochem; 2008 May; 105(3):750-62. PubMed ID: 18179476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
    Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
    Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
    Gouhier C; Chalon S; Aubert-Pouessel A; Venier-Julienne MC; Jollivet C; Benoit JP; Guilloteau D
    Synapse; 2002 Jun; 44(3):124-31. PubMed ID: 11954043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
    Kordower JH; Olanow CW; Dodiya HB; Chu Y; Beach TG; Adler CH; Halliday GM; Bartus RT
    Brain; 2013 Aug; 136(Pt 8):2419-31. PubMed ID: 23884810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection by tetrahydroxystilbene glucoside in the MPTP mouse model of Parkinson's disease.
    Zhang L; Huang L; Chen L; Hao D; Chen J
    Toxicol Lett; 2013 Oct; 222(2):155-63. PubMed ID: 23911879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional and temporal expression of the peripheral benzodiazepine receptor in MPTP neurotoxicity.
    Kuhlmann AC; Guilarte TR
    Toxicol Sci; 1999 Mar; 48(1):107-16. PubMed ID: 10330690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.
    Gross CE; Ravenscroft P; Dovero S; Jaber M; Bioulac B; Bezard E
    J Neurochem; 2003 Mar; 84(6):1246-55. PubMed ID: 12614325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The weaver GIRK2 mutation leads to decreased levels of serum thyroid hormone: characterization of the effect on midbrain dopaminergic neuron survival.
    Blum M; Weickert C; Carrasco E
    Exp Neurol; 1999 Dec; 160(2):413-24. PubMed ID: 10619558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anatomical and functional reconstruction of the nigrostriatal pathway by intranigral transplants.
    Gaillard A; Decressac M; Frappé I; Fernagut PO; Prestoz L; Besnard S; Jaber M
    Neurobiol Dis; 2009 Sep; 35(3):477-88. PubMed ID: 19616502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model.
    Verhave PS; Jongsma MJ; Van Den Berg RM; Vanwersch RA; Smit AB; Philippens IH
    Neuropharmacology; 2012 Mar; 62(4):1700-7. PubMed ID: 22178201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.